中国中医药信息杂志
中國中醫藥信息雜誌
중국중의약신식잡지
CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE
2014年
3期
21-23
,共3页
芪连扶正胶囊%晚期非小细胞肺癌%维持治疗
芪連扶正膠囊%晚期非小細胞肺癌%維持治療
기련부정효낭%만기비소세포폐암%유지치료
Qilian Fuzheng capsule%advanced non-small cell lung cancer%maintenance treatment
目的:探讨分析芪连扶正胶囊维持治疗晚期非小细胞肺癌的临床效果及优势。方法将符合纳入标准的晚期非小细胞肺癌患者随机分为观察组和对照组,2组各32例。对照组给予最佳支持治疗,观察组在对照组治疗基础上给予芪连扶正胶囊,每次4粒,每日3次,口服。观察随访比较2组患者肿瘤控制率、生活质量、无疾病进展生存期与总生存期。结果芪连扶正胶囊维持治疗晚期非小细胞肺癌可改善患者生活质量;观察组和对照组无疾病进展生存期分别为5.4、4.1个月(P<0.05),总生存期分别为12.3、10.6个月(P>0.05);肿瘤控制率观察组为77.42%(24/31),对照组为60.00%(18/30),2组比较差异无统计学意义(P>0.05)。结论芪连扶正胶囊维持治疗晚期非小细胞肺癌具有可行性。
目的:探討分析芪連扶正膠囊維持治療晚期非小細胞肺癌的臨床效果及優勢。方法將符閤納入標準的晚期非小細胞肺癌患者隨機分為觀察組和對照組,2組各32例。對照組給予最佳支持治療,觀察組在對照組治療基礎上給予芪連扶正膠囊,每次4粒,每日3次,口服。觀察隨訪比較2組患者腫瘤控製率、生活質量、無疾病進展生存期與總生存期。結果芪連扶正膠囊維持治療晚期非小細胞肺癌可改善患者生活質量;觀察組和對照組無疾病進展生存期分彆為5.4、4.1箇月(P<0.05),總生存期分彆為12.3、10.6箇月(P>0.05);腫瘤控製率觀察組為77.42%(24/31),對照組為60.00%(18/30),2組比較差異無統計學意義(P>0.05)。結論芪連扶正膠囊維持治療晚期非小細胞肺癌具有可行性。
목적:탐토분석기련부정효낭유지치료만기비소세포폐암적림상효과급우세。방법장부합납입표준적만기비소세포폐암환자수궤분위관찰조화대조조,2조각32례。대조조급여최가지지치료,관찰조재대조조치료기출상급여기련부정효낭,매차4립,매일3차,구복。관찰수방비교2조환자종류공제솔、생활질량、무질병진전생존기여총생존기。결과기련부정효낭유지치료만기비소세포폐암가개선환자생활질량;관찰조화대조조무질병진전생존기분별위5.4、4.1개월(P<0.05),총생존기분별위12.3、10.6개월(P>0.05);종류공제솔관찰조위77.42%(24/31),대조조위60.00%(18/30),2조비교차이무통계학의의(P>0.05)。결론기련부정효낭유지치료만기비소세포폐암구유가행성。
Objective To observe the effect and analyze the advantage of Qilian Fuzheng capsule in maintenance treatment of advanced non-small cell lung cancer. Methods The advanced non-small cell lung cancer patients were randomly divided into observation group and control group, 32 cases in each group. The control group was given the best supportive care, and the observation group was given Qilian Fuzheng capsule 4 capsules three times daily additionally. The tumor control rate, quality of life, PFS and OS of the two groups were compared by follow-up. Results Qilian Fuzheng capsule maintenance treatment of advanced non-small cell lung cancer improved the quality of life. PFS of observation group and control group was 5.4 months and 4.1 months, respectively (P<0.05), and OS of the two groups was 12.3 months and 10.6 months, respectively (P>0.05). The tumor control rate of observation group was 77.42% (24/31), control group was 60.00% (18/30), with no significant difference (P>0.05). Conclusion Qilian Fuzheng capsule is a feasible application in maintenance treatment of advanced non-small cell lung cancer.